Premium
PHASE 1B KEYNOTE‐013 STUDY OF PEMBROLIZUMAB IN PATIENTS WITH CLASSIC HODGKIN LYMPHOMA AFTER BRENTUXIMAB VEDOTIN FAILURE: RESULTS OF >4 YEARS OF FOLLOW‐UP
Author(s) -
Zinzani P.L.,
Armand P.,
Ribrag V.,
Michot J.,
Kuruvilla J.,
Zhu Y.,
Farooqui M.,
Nahar A.,
Moskowitz C.H.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.106_2630
Subject(s) - medicine , brentuximab vedotin , pembrolizumab , autologous stem cell transplantation , oncology , cohort , population , lymphoma , progression free survival , surgery , chemotherapy , hodgkin lymphoma , cancer , immunotherapy , environmental health
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom